COPE: The Carboprost or Oxytocin Postpartum haemorrhage Effectiveness study
Data-sharing agreement from NHS England Data Uses Register. Evidence status: source reported.
- Organisation
- BANGOR UNIVERSITY
- Published
- 2026-08-24
- Source reference
- DARS-NIC-781704-X8W4H-v0.3
- Jurisdiction
- England
- Licence
- Open Government Licence v3.0, subject to NHS England terms and exclusions
The Data will be used for the purpose of a clinical trial: The Carboprost or Oxytocin Postpartum haemorrhage Effectiveness study (COPE) The Data will be used to answer the following questions: 1. To compare carboprost with oxytocin as the initial treatment for women with clinically diagnosed postpartum haemorrhage (PPH) after giving birth in UK hospitals. 2. To assess the relative cost‑effectiveness of carboprost compared with oxytocin when used as initial treatments for PPH. 3. To explore the views of participants and their carers about their experiences of the two treatments…
- Register reference
- DARS-NIC-781704-X8W4H-v0.3
- Applicant type
- Academic
- Data controllers
- BANGOR UNIVERSITY, UNIVERSITY OF LIVERPOOL
- Agreement period
- 2026-08-24 to 2028-08-23
- For commercial purposes (as marked in the register)
- No
- Release files listed by NHS England
- 0
Data approved
- Emergency Care Data Set (ECDS)
- Hospital Episode Statistics Admitted Patient Care (HES APC)
- Hospital Episode Statistics Critical Care (HES Critical Care)
- Hospital Episode Statistics Outpatients (HES OP)
Objective, as published
The Data will be used for the purpose of a clinical trial: The Carboprost or Oxytocin Postpartum haemorrhage Effectiveness study (COPE) The Data will be used to answer the following questions: 1. To compare carboprost with oxytocin as the initial treatment for women with clinically diagnosed postpartum haemorrhage (PPH) after giving birth in UK hospitals. 2. To assess the relative cost‑effectiveness of carboprost compared with oxytocin when used as initial treatments for PPH. 3. To explore the views of participants and their carers about their experiences of the two treatments and the consent process.
Expected benefits, as published
The findings of this research study are expected to contribute to evidence-based decision-making for policy-makers, local decision-makers such as doctors, and patients to inform best practice to improve the care, treatment and experience of health care users relevant to the subject matter of the study. The use of the data could: • lead to the identification or improvement of treatments or interventions, or health and care system design to improve health and care outcomes or experience. • inform planning health services and programmes, for example to improve equity of access, experience and outcomes. • inform decisions on how to effectively allocate and evaluate funding according to health needs. • support knowledge creation or exploratory research (and the innovations and d…
Benefits reported by the applicant
Yielded Benefits is not a requirement for new applications.
This is the applicant's own account; OpenHDI has not verified it.
Source: https://digital.nhs.uk/services/data-access-request-service-dars/data-uses-register. Captured 2026-11-05.
Limitations: Data-sharing agreement as published in NHS England's Data Uses Register. An agreement permits access; actual data releases are listed separately. Expected and yielded benefits are as reported by the applicant and have not been independently verified. Long text fields can be cut off in NHS England's spreadsheet export at Excel's 32,767-character cell limit.